The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
New Insights Into Transmission, Diagnosis, and Drug Treatment of <EMPH TYPE="ITAL">Pneumocystis carinii</EMPH> Pneumonia
Abstract
Pneumocystis carinii has been recognized as a human pathogen for nearly 50 years. We present a case of P carinii infection that typifies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic. The high incidence of P carinii pneumonia in persons infected with human immunodeficiency virus (HIV) has served to focus laboratory and clinical research efforts on better understanding the biology of the organism and on improving diagnosis, treatment, and prevention of this disease. Although inability to culture P carinii has hampered research efforts, molecular and immunologic approaches have led to the recognition that the organism represents a family of fungi with a very restricted host range and have allowed characterization of clinically relevant antigens and enzymes. Molecular epidemiologic studies have identified more than 50 strains of human-derived P carinii and have suggested that recently acquired infection, as opposed to reactivation of latent infection, may account for many cases of clinical disease. Diagnosis has been improved by the development of organism-specific monoclonal antibodies and, more recently, by polymerase chain reaction using multicopy gene targets, together with induced sputum or oral wash samples. Chemotherapeutic prophylaxis is very effective in preventing P carinii pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line agent for both therapy and prophylaxis. Prophylaxis needs to be administered only during periods of high risk; in HIV-infected patients responding to effective antiretroviral therapies, prophylaxis no longer needs to be lifelong. Molecular studies have identified mutations in the target of sulfa drugs that appear to represent emerging resistance in P carinii. Resistance to atovaquone, a second-line agent, may also be developing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brooks, D. R., Wang, P., Read, M., Watkins, W. M., Sims, P. F. G., & Hyde, J. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00397.x · Cited by 369
Helweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., & Lundgren, B. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03320-6 · Cited by 274 · cited 2×
“In a Danish study, the prevalence appeared to decline again after 1997, possibly because sulfa drug use was declining.(86)”
BackgroundBeard, C. B., Carter, J. L., Keely, S. P., Huang, L., Pieniazek, N. J., Moura, I. N. S., Roberts, J. M., Hightower, A. W., Bens, M. S., Freeman, A. R., et al. (2000) · Emerging infectious diseases · doi:10.3201/eid0603.000306 · Cited by 241
Nzila, A. M., Mberu, E. K., Sulo, J., Dayo, H., Winstanley, P. A., Sibley, C. H., & Watkins, W. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.991-996.2000 · Cited by 232
Dihydropteroate synthase polymorphisms in Pneumocystis carinii.
Lane, B. R., Ast, J. C., Hossler, P. A., Mindell, D. P., Bartlett, M. S., Smith, J. W., & Meshnick, S. R. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.2.482 · Cited by 176
Self-citationKazanjian, P., Locke, A. B., Hossler, P. A., Lane, B. R., Bartlett, M. S., Smith, J. W., Cannon, M., & Meshnick, S. R. (1998) · AIDS · doi:10.1097/00002030-199808000-00009 · Cited by 171
Ma, L., Borio, L., Masur, H., & Kovacs, J. A. (1999) · The Journal of Infectious Diseases · doi:10.1086/315148 · Cited by 169 · cited 1×
“One other important piece of information was added by Ma et al.(83) Their study was the first to look for mutations in DHFR, the target of trimethoprim.”
BackgroundSelf-citationKazanjian, P., Armstrong, W., Hossler, P. A., Burman, W., Richardson, J., Lee, C., Crane, L., Katz, J., & Meshnick, S. R. (2000) · The Journal of Infectious Diseases · doi:10.1086/315719 · Cited by 164 · cited 3×
“Mutations were absent or infrequent before 1993 and then became quite common.(84,85) In a Danish study, the prevalence appeared to decline again after 1997, possibly because sulfa drug use was declining.”
BackgroundEmergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.
Martin, J. N., Rose, D. A., Hadley, W. K., Perdreau‐Remington, F., Lam, P. K., & Gerberding, J. L. (1999) · The Journal of Infectious Diseases · doi:10.1086/315132 · Cited by 126
Kai, M., Matsuoka, M., Nakata, N., Maeda, S., Gidoh, M., Maeda, Y., Hashimoto, K., Kobayashi, K., & Kashiwabara, Y. (1999) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1999.tb13737.x · Cited by 81
Walzer, P. D., Foy, J., Steele, P., Kim, C. K., White, M., Klein, R. S., Otter, B. A., & Allegra, C. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.1935 · Cited by 67
Cited by
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Azoulay, É., Mokart, D., Lambert, J., Lemiale, V., Rabbat, A., Kouatchet, A., Vincent, F., Gruson, D., Bruneel, F., Epinette-Branche, G., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0018oc · Cited by 300
Fishman, J. A., Gans, H., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13587 · Cited by 293
The management of brain edema in brain tumors
Kaal, E. C. A., & Vecht, C. J. (2004) · Current Opinion in Oncology · doi:10.1097/01.cco.0000142076.52721.b3 · Cited by 292
CROTHERS, K., HUANG, L., MORRIS, A., FOX, M., GRONER, G., TURNER, J. R., MERRIFIELD, C., EISER, S., FRIEDLY, J., GRAVARI, E., et al. (2003) · Journal of Eukaryotic Microbiology · doi:10.1111/j.1550-7408.2003.tb00648.x · Cited by 12
Metadata
- Authors
- Kovacs, J. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-11-21
- Volume
- 286
- Issue
- 19
- Pages
- 2450
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2139053777
- Cited by
- 219
- References
- 11
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.